AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04340531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive phone counseling
Study NCT04340531 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Cessation Counseling
Description: Receive phone counseling
Study NCT04340531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Undergo training
Study NCT04340531 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Undergo training
Study NCT05099510 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NatrunixTM
Description: The active ingredient in the drug product NatrunixTM is XB2001, a recombinant human IgG4 monoclonal antibody specific for human interleukin-1-alpha (IL-1-alpha). The entire XB2001 heavy and light chain sequences are identical to those found in naturally-occurring human IgG4-kappa, with the light and heavy chain variable regions being identical to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy individual.
Study NCT05099510 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control for NatrunixTM subcutaneous injection.
Study NCT05098132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STK-012
Description: pegylated alpha/beta-biased engineered interleukin-2
Study NCT05098132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: anti-PD-1 humanized monoclonal antibody
Study NCT05098132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: antifolate chemotherapy
Study NCT05143541 — intervention group
Intervention type: DEVICE
Intervention: AEON Endostapler
Description: Surgery with AEON Endostapler
Study NCT06438939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy for diagnostical purposes
Description: Incisional biopsy is the current golden standard for OPMD/OSCC diagnosis. Yet, the site it shall be performed is choosen by clinician at naked eyes. We will compare and study the results of performing the common golden standard biopsy site when guided by NBI.
Study NCT06438939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy for diagnostical purposes
Description: Incisional biopsy is the current golden standard for OPMD/OSCC diagnosis. Yet, the site it shall be performed is choosen by clinician at naked eyes. We will compare and study the results of performing the common golden standard biopsy site when guided by NBI.
Study NCT06134505 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of Barrier cream group 1 in the healing of diaper dermatitis
Description: In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that Barrier cream 1 would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved.
Study NCT05329532 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modi-1/Modi-1v
Description: Modi-1/Modi-1v administered intradermally (i.d.) using the MicronJet600™ microneedle device (NanoPass).
Study NCT05329532 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (exploratory cohorts) will be administered by intravenous infusion on Day 8, prior to tumour resection surgery at 6 weeks.
Study NCT05329532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet600™ microneedle device (NanoPass)
Description: Intradermal injection device
Study NCT06248060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preanaesthetic classical physical consultation
Description: Pre-anaesthetic classical consultation before teleconsultation implementation
Study NCT06248060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preanaesthetic teleconsultation
Description: Pre-anaesthetic consultation by telephone for eligible patients according to the criteria set
Study NCT04928443 — intervention group
Intervention type: OTHER
Intervention: Scar dressing group
Description: Patients treated with scar dressing for surgical scar care are invited to participate this study and allocated in scar dressing group despite the length of caring period.
Study NCT04928443 — intervention group
Intervention type: OTHER
Intervention: Regular care group
Description: Patients receiving regular scar care are retrospectively identified with matching factors, such as gender, age, length of surgical wound and surgical procedure.
Study NCT04746222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral capsule faecal microbiota transplantation
Description: Single dose of 30 oral capsules containing healthy donor stool from a stool bank
Study NCT04746222 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of 30 oral placebo capsules
Study NCT06337032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Low Dose)
Description: 30/120/15 mg FDC tablet administered orally
Study NCT05648578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki attempt
Description: Four reiki sessions were applied twice a week, on the same days of the week, lasting 25-35 minutes each.
Study NCT05332730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2506 injection
Description: 50 mg, subcutaneous administration
Study NCT05332730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simponi® (EU commercially available product)
Description: 50 mg, subcutaneous administration
Study NCT05332730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simponi® (US commercially available product)
Description: 50 mg, subcutaneous administration
Study NCT05538533 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 46 Gy Radiation Therapy
Description: Dose per fraction of 4.6.
Study NCT05538533 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 40 Gy Radiation Therapy
Description: Dose per fraction 5.7.
Study NCT05538533 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 35 Gy Radiation Therapy
Description: Dose per fraction 7.0.
Study NCT05806086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panfoshu+Conventional Treatment（program-A）
Description: On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken orally once a day on an empty stomach, one capsule at a time. 1 course of treatment was 6mon, which was taken 10 days a month, stopped for 20 days for 3 months, and observed for another 3 months(unmedicated). Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
Study NCT05806086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panfoshu+Conventional Treatment（program-B）
Description: On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken for 30 days in the first month, stopped in the second month, taken for 10 days and stopped for 20 days in a row for 3 months, and finally observed for 1 month. Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
Study NCT05806086 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Treatment
Description: Patients in this group were treated with only the conventional treatment.
Study NCT06319131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: Using the transjugular approach, TIPS was created under local anesthesia. The first branch of the left or right portal vein (PV) was punctured by RUPS-100 set guided by digital subtraction angiography. After successful access into PV, direct portography was performed and all visible varices and/or concurrent spontaneous portosystemic shunts (SPSS) were embolized with coils and n-butyl cyanoacrylate. A polytetrafluoroethylene-covered stent (Viatorr Endoprosthesis, GORE and Associates, Flagstaff, Arizona, USA) with a diameter of 8 mm was implanted and fully dilated.
Study NCT06319131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin
Description: Nadroparin calcium will be subcutaneously injected with the dose of 85IU/kg q12h
Study NCT03938467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiseptic Cleanser
Description: Contains 0.05% Chlorhexidine gluconate in sterile water for irrigation. The mechanical action of the Irrisept system removes bacteria and debris without harming underlying tissues. Irrisept has demonstrated broad spectrum bactericidal activity against antibiotic-resistant strains. Its contents are wrapped in two sequential sterilization wraps which repel water blood, and saline, making it effective against both air and water borne bacteria.
Study NCT05194657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enhanced depth of focus IOL
Description: Acrysof IQ Vivity, enhanced depth of focus IOL
Study NCT05194657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: monofocal IOL
Description: Acrysof IQ, monofocal IOL
Study NCT06134505 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of Barrier cream 2 in the healing of diaper dermatitis
Description: In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that barrier cream 2 would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved.
Study NCT05119673 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bi-plane sonographic view to difficult peripheral vascular access using Butterfly iQ+®
Description: Bi-plane Butterfly iQ+® sonographic visualization will be used to help Emergency Department operators to get a venous peripheral access in a population of patients considered difficult for this task based on their history or the present clinical situation.
Study NCT05534529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezafungin Acetate
Description: This is a Phase 1, multicentre, open-label, single-dose study. The study will be conducted at 10 sites across at least 3 countries in Europe.
Study NCT06451848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab Injection (T, Solution for injection)
Description: A single dose of subcutaneous injection of Genakumab（Solution for injection, liquid formulation）200 mg on Day 1
Study NCT06134505 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of olive oil in the healing of diaper dermatitis
Description: In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that olive oil would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved.
Study NCT05379127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-empowered follow up
Description: The patient-empowered follow-up protocol consists of patient-reported outcome measures (PROMs), self-assessment tools and clinical assessment including physical examination. Radiographs will only be taken when progression of the scoliosis (curve progression) or postoperative complications are suspected based on test results and based on the criteria of so called 'sense of alarm'.~Note: Sense of alarm ('niet pluis') is based on any deterioration on the above-mentioned PROMs, self-assessment tool, and clinician-based measurement instruments, which is a signal for the treating physician to consider when a radiograph is appropriate. Sense of alarm is described as any other concern by the orthopaedic surgeon, parent or child which warrants a radiograph. For both the Bunnell Scoliometer (clinical assessment tool) and the Scolioscoop (patient self-assessment tool) a threshold of ≥4° is used.
Study NCT05379127 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard follow-up
Description: Routine radiographs are taken at each follow up visit during standard care (to detect possible curve progression or rule out postoperative complications).
Study NCT06337032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (High Dose TOS)
Description: 15/60/7.52 mg TOS administered orally
Study NCT06337032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Low Dose TOS)
Description: 7.5/30/3.76 mg TOS administered orally
Study NCT06337032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Lowest Dose TOS)
Description: 3.76/15/1.88 mg TOS administered orally
Study NCT06337032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3rd ARV Agent
Description: A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country
Study NCT05409404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise + hot water immersion
Description: Light to moderate intensity aerobic exercise for 30 minutes, followed by 30 minutes of hot water immersion at 40°C.
Study NCT05409404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise + thermoneutral water immersion
Description: Light to moderate intensity aerobic exercise for 30 minutes, followed by 30 minutes of thermoneutral water immersion at 34°C.
Study NCT06337032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide reverse transcriptase inhibitors (NRTI)
Description: NRTIs administered as defined by the investigator, according to the prescribing information. NRTIs may include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), or emtricitabine (FTC)
Study NCT06337032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Administered according to the prescribing information
Study NCT06337032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: Administered according to the prescribing information
Study NCT06337032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir Boosted with ritonavir (LPV/r)
Description: Administered according to the prescribing information
Study NCT05434078 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthofeet Shoes
Description: Participants will wear a pair of Orthofeet shoes to wear for 6 weeks
Study NCT06252584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccines, Peptide
Description: Multi-peptide vaccine cocktail comprising 9 different immunopeptidome-defined mutated and non-mutated AML/ leukemia stem and progenitor cell (LSC)-associated HLA class I and HLA class II peptides. The vaccine cocktail is synthesized and formulated in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen.
Study NCT05507333 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Gedea pessary
Description: Daily administration of the Gedea pessary during 6 days
Study NCT05982678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd 5.4mg/kg on a three weekly (21 day) basis, with the goal of 16 cycles leading to a treatment period of year, including local treatment. The first 8 cycles of T-DXd are administered neo-adjuvant, and 8 cycles adjuvant, after completion of local treatment.
Study NCT05829265 — intervention group
Intervention type: BEHAVIORAL
Intervention: A digital social intervention by primary care clinicians.
Description: The intervention in this study will involve a structured consultation with a primary care clinician (e.g. a general practitioner (GP) or practice nurse) to promote online peer support, followed by engagement with the OHC of the Asthma + Lung UK (ALUK) charity. The intervention will either be delivered in person (in the general practices) or virtually. The aim is for the intervention to involve a face-to-face, one-off consultation, lasting approximately 30 minutes, during which a primary care clinician will:~* Signpost and sign patients up to the ALUK OHC, by thoroughly explaining terms of conditions of use and providing log in details.~* Introduce norms and values for passive (just reading) and active (writing OHC posts) participation.~* Encourage seeking and offering self-management information and support, by emphasising that the OHC could be used ad hoc (e.g. when feeling unwell, or when there are information or emotional needs).
Study NCT05487599 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LY3884961
Description: • LY3884961 is a replication-incompetent recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
Study NCT06276335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate implant placement and guided bone regeneration (Test)
Description: In this group, immediately after tooth extraction, a tapered bone level implant (Straumann BLX Implant System, Roxolid, Straumann AG, Basel, Switzerland) will be placed in an ideal prosthetically oriented position to achieve primary stability following the manufacture's guidelines. A prefabricated surgical template based on 3D pre-extraction planning will be used to place the implant. The jumping distance between the implant and the residual buccal bone will be measured and filled with slow resorption bone graft material (Bio-Oss®, Geistlich, Wolhusen, Switzerland) as per standard of practice.
Study NCT06276335 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late implant placement and guided bone regeneration (Control)
Description: A tapered bone level implant (Straumann BLX Implant System, Roxolid, Straumann AG, Basel, Switzerland) will be placed after complete bone healing (4 - 6 months after tooth extraction) in an ideal prosthetically oriented position to achieve primary stability following the manufacture's guidelines. Guided bone regeneration (GBR) will be performed simultaneously with the aim to re-establish the bone contour and treat any fenestration/dehiscence if needed. A bovine osteoconductive graft (Bio-Oss®, Geistlich, Wolhusen, Switzerland) will be loosely compacted on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland).
Study NCT04110132 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ganglion impar block with Bupivacaine.
Description: Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.~Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative.
Study NCT06451848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab for Injection (R, Powder for solution for injection)
Description: A single dose of subcutaneous injection of Genakumab（Powder for solution for injection, lyophilized formulation) 200 mg on Day 1
Study NCT06332859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resilience training
Description: The resilience training consists of two sessions of psychological group therapy, each lasting 100 minutes, with a special focus on resilience. Additionally, there are two sessions of relaxation training, known as 'heart yoga', each lasting 25 minutes.
Study NCT04893707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: adults and teenagers (12 \~ 18 years) with weight ≥60 kg : 600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC.~teenagers (12 \~ 18 years) with weight ≥30 kg and \<60kg : 400mg for 1st dose, and then 200 mg, every 2 weeks and up to 1 year, SC.
Study NCT06018454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handout on PGT-A
Description: Educational handout on PGT-A
Study NCT06018454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handout on PGT-A and genetic counseling
Description: Handout on PGT-A and genetic counseling session with a genetic counselor on PGT-A
Study NCT05098132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: platinum chemotherapy